Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-048905
Filing Date
2025-04-02
Accepted
2025-04-02 09:06:50
Documents
1
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 4025
  Complete submission text file 0000950170-25-048905.txt   5443
Mailing Address C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Business Address
Sullivan Lara (Reporting) CIK: 0001769457 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40881 | Film No.: 25802346

Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Issuer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)